These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37841729)

  • 1. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
    Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
    Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.
    Ta A; Kühne F; Laurenz M; von Eiff C; Warren S; Perdrizet J
    Infect Dis Ther; 2024 Jun; 13(6):1333-1358. PubMed ID: 38733494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults.
    Marbaix S; Mignon A; Taelman A; Averin A; Atwood M; Vietri J
    Expert Rev Vaccines; 2023; 22(1):1008-1021. PubMed ID: 37872765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
    de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
    BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Rey-Ares L; Ta A; Freigofaite D; Warren S; Mac Mullen M; Carballo C; Huang L
    Vaccine; 2024 Oct; 42(23):126043. PubMed ID: 38879409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23.
    Olsen J; Schnack H; Skovdal M; Vietri J; Mikkelsen MB; Poulsen PB
    J Med Econ; 2022; 25(1):1240-1254. PubMed ID: 36426797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
    Cantarero D; Ocaña D; Onieva-García MÁ; Rodríguez-García J; Gálvez P; Méndez C; Crespo C; López-Ibáñez de Aldecoa A
    Vaccine; 2023 Aug; 41(36):5342-5349. PubMed ID: 37479615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly.
    Hoshi SL; Shono A; Seposo X; Okubo R; Kondo M
    Vaccine; 2022 Nov; 40(49):7057-7064. PubMed ID: 36273987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population.
    Fridh AC; Palmborg A; Ta A; Freigofaite D; Warren S; Perdrizet J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2400751. PubMed ID: 39279284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
    Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
    Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
    Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
    Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.
    Choi YH; Bertran M; Litt DJ; Ladhani SN; Miller E
    Lancet Public Health; 2024 Sep; 9(9):e654-e663. PubMed ID: 39153492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
    Smith KJ; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK
    Infect Dis Ther; 2022 Aug; 11(4):1683-1693. PubMed ID: 35831685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
    Mendes D; Averin A; Atwood M; Sato R; Vyse A; Campling J; Weycker D; Slack M; Ellsbury G; Mugwagwa T
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1285-1295. PubMed ID: 36225103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
    Huang L; Wasserman M; Grant L; Farkouh R; Snow V; Arguedas A; Chilson E; Sato R; Perdrizet J
    Vaccine; 2022 Aug; 40(33):4700-4708. PubMed ID: 35753839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany.
    Kühne F; Achtert K; Püschner F; Urbanski-Rini D; Schiller J; Mahar E; Friedrich J; Atwood M; Sprenger R; Vietri J; von Eiff C; Theilacker C
    Expert Rev Vaccines; 2023; 22(1):921-932. PubMed ID: 37881844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.